You are in: eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease Dental AbscessArticle Last Updated: Oct 12, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Karen Schneider, MD, Assistant Professor, Department of Pediatrics, Division of Pediatric Emergency Medicine, Johns Hopkins University School of Medicine Karen Schneider is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and American Medical Association Editors: Halim Hennes, MD, MS, Pediatric Emergency Medicine Research Director, Professor, Departments of Pediatrics and Emergency Medicine, Medical College of Wisconsin; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine; Wayne Wolfram, MD, MPH, Clinical Associate Professor, Departments of Pediatrics, Children's Hospital and University of Cincinnati; Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine; Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine Author and Editor Disclosure Synonyms and related keywords: dental abscess, odontogenic abscess, tooth abscess, dentoalveolar abscess, periapical abscess, periodontal abscess, pericoronitis, tooth infection, infected tooth, dental caries, pulpitis, baby-bottle tooth decay, BBTD, Ludwig angina, Ludwig's angina, simple dentoalveolar abscess, odontogenic infection, pulpitides, early-childhood caries, caries, gingivitis, plaque INTRODUCTIONBackgroundA dentoalveolar abscess is an acute lesion characterized by localization of pus in the structures that surround the teeth. Most patients are treated easily with analgesia, antibiotics, drainage, and/or referral to a dentist or oral-maxillofacial surgeon. However, the physician should be aware of potential complications of simple dentoalveolar abscess. PathophysiologyThe term dentoalveolar abscess comprises 3 distinct processes, as follows:
Odontogenic infections are polymicrobial, with an average of 4-6 different causative bacteria. The dominant isolates are strictly anaerobic gram-negative rods and gram-positive cocci, in addition to facultative and microaerophilic streptococci. Anaerobic bacteria outnumber aerobes 2-3:1.1 In general, strictly anaerobic gram-negative rods are more pathogenic than facultative or strictly anaerobic gram-positive cocci. Generally, a nonpathologic resident bacterium gains entry when the host's defenses are breached, rather than when a nontypical microorganism is introduced. The predominant species include those of Bacteroides, Fusobacterium, Peptococcus, and Peptostreptococcus, as well as Streptococcus viridans. Mortality/MorbidityMortality is rare and is usually due to airway compromise. Morbidity relates to pain, probable tooth loss, and dehydration. See Complications. RaceNo race predilection is observed. SexNo sex predilection is noted. Age
CLINICALHistory
Physical
Causes
DIFFERENTIALSPeritonsillar Abscess
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Penicillin (Pfizerpen, Pen-Vee K, Beepen-VK) |
|---|---|
| Description | DOC; effective against most aerobes and anaerobes. Penicillin has traditionally been considered the DOC for odontogenic infections. The efficacy of penicillin is a concern because of the emergence of beta-lactamase–producing organisms, which confer resistance to penicillins. Penicillin still remains the antibiotic of choice for mild-to-moderate infections. Inhibits the biosynthesis of cell wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations are reached and most effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. Penicillin V (phenoxymethyl penicillin) is administered orally, whereas aqueous penicillin G is administered IV or IM. |
| Adult Dose | Penicillin V: 250-500 mg PO q6-8h Penicillin G: 2-24 million U/d IV/IM divided q4-6h |
| Pediatric Dose | Penicillin V: 15-62.5 mg/kg/d (25,000-100,000 U/kg/d) PO divided q4-8h Penicillin G: 100,000-400,000 U/kg/d divided q4-6h; not to exceed 24 million U/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid can increase effects of penicillin; coadministration of tetracyclines can decrease effects of penicillin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function |
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Acts by binding to 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected. Concentrates in phagocytes and fibroblasts, as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues. Treats mild-to-moderate microbial infections. |
| Adult Dose | Day 1: 500 mg PO Days 2-5: 250 mg/d PO Alternatively, 1 g PO once |
| Pediatric Dose | <6 months: Not established >6 months: Day 1: 10 mg/kg PO once; not to exceed 500 mg/d Days 2-5: 5 mg/kg/d PO; not to exceed 250 mg/d |
| Contraindications | Documented hypersensitivity; hepatic impairment; do not administer with pimozide |
| Interactions | May increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Site reactions can occur with IV route; bacterial or fungal overgrowth may result from prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in patients who are hospitalized, geriatric, or debilitated |
| Drug Name | Metronidazole (Flagyl) |
|---|---|
| Description | Effective against only obligate anaerobes. Alternative for patients who are allergic to penicillin. Consider the combination of penicillin with metronidazole because metronidazole compensates for limited activity of penicillin against beta-lactamase–producing stains of anaerobes. Compliance must be considered with a 2-drug regimen. |
| Adult Dose | Loading dose: 15 mg/kg or 1 g for a 70-kg adult IV over 1 h Maintenance dose: 6 h following loading dose, administer 7.5 mg/kg or 500 mg for a 70-kg adult IV over 1 h q6-8h; not to exceed 4 g/d |
| Pediatric Dose | 30 mg/kg/d PO/IV divided q6h; not to exceed 4 g/d |
| Contraindications | Documented hypersensitivity; first trimester of pregnancy |
| Interactions | Cimetidine may increase toxicity of metronidazole; may increase effects of anticoagulants; may increase toxicity of lithium and phenytoin; disulfiramlike reaction may occur with orally ingested ethanol |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Considered by many as first-line therapy because of emergent penicillin resistance. Excellent activity against oral aerobes and anaerobes; penetrates bone and abscess cavities, but its use is limited because of the danger of inducing pseudomembranous colitis; no more effective than penicillin against anaerobes. Use in patients who are allergic to penicillin. |
| Adult Dose | 150-450 mg PO q6-8h; not to exceed 1.8 g/d 600-1200 mg/d IV/IM divided q6-8h |
| Pediatric Dose | 20-30 mg/kg/d PO divided q6h; not to exceed 1.8 g/d 25-40 mg/kg/d IV/IM divided q6-8h |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade, induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Amoxicillin and clavulanate (Augmentin) |
|---|---|
| Description | Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Addition of clavulanate inhibits beta-lactamase–producing bacteria. Good alternative antibiotic for patients allergic or intolerant to the macrolide class. Is usually well tolerated and provides good coverage to most infectious agents. Not effective against Mycoplasma and Legionella species. The half-life of oral dosage form is 1-1.3 h. Has good tissue penetration but does not enter cerebrospinal fluid. For children aged 3 mo or older, base dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5), do not use 250-mg tab until child weighs >40 kg. |
| Adult Dose | 500 mg PO tid for 7-10 d |
| Pediatric Dose | <3 months: 125 mg/5mL PO susp; 30 mg/kg/d (based on amoxicillin component) PO divided bid for 7-10 d >3 months: if using 200 mg/5 mL or 400 mg/5 mL susp, 45 mg/kg/d PO q12h; if using 125 mg/5 mL or 250 mg/5 mL susp, 40 mg/kg/d PO q8h for 7-10 d >40 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding; may act synergistically against selected microorganisms when coadministered with aminoglycosides; coadministration with allopurinol may increase incidence of amoxicillin rash; may decrease efficacy of oral contraceptives when administered concomitantly |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment; diarrhea may occur; cross-allergy may occur with other beta-lactams and cephalosporins |
| Drug Name | Cefoxitin (Mefoxin) |
|---|---|
| Description | Second-generation cephalosporin with activity against some gram-positive cocci, gram-negative rod infections, and anaerobic bacteria. Inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins; inhibits final transpeptidation step of peptidoglycan synthesis, resulting in cell wall death. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin. |
| Adult Dose | 2 g IV q6h and 100 mg IV doxycycline q12h; continue at least 4 d and at least 48 h after improvement; then, 100 mg PO doxycycline bid 10-14 d |
| Pediatric Dose | 80-160 mg/kg/d IV/IM divided q4-8h; not to exceed 12 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects of cefoxitin; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy |
| Drug Name | Moxifloxacin (Avelox) |
|---|---|
| Description | Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription. |
| Adult Dose | 400 mg/d PO/IV |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; known Q-T prolongation, concurrent administration of drugs that cause Q-T prolongation |
| Interactions | Antacids and electrolyte supplements reduce absorption; loop diuretics, probenecid, cimetidine increase serum levels; NSAIDs enhance CNS-stimulating effect; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); ferrous sulfate decreases bioavailability (administer moxifloxacin 4 h prior to or 8 h following ferrous sulfate); coadministration with drugs that prolong QTc interval (quinidine, procainamide, amiodarone, sotalol, erythromycin, tricyclic antidepressants) increase risk of life-threatening arrhythmia |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, periodically evaluate organ-system functions (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy; fluoroquinolones have induced seizures in patients with CNS disorders and have caused tendinitis or tendon rupture |
| Media file 1: Obvious swelling of the right cheek. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Side view. Fluctuant mass extending toward the buccal side of the gum end to the gingival-buccal reflection. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Gingiva with swelling and erythema. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Oct 12, 2007